Healthcare Business Report: Life Technologies SHIPS Ion System, Omnicare’s NEWS
Johnson & Johnson’s (NYSE:JNJ) Janssen Pharmaceuticals, along with ALZA Corporation, have resolved pending legislation in the United States with Impax Laboratories, Inc. (NASDAQ:IPXL) and Teva Pharmaceuticals USA (NYSE:TEVA) concerning the production and sale of generic formulations of Concerta. By the terms of the settlement, ALZA will grant Impax and Teva a license to sell generic versions of the drug on July 14, 2013 or earlier.
Don’t Miss: Johnson & Johnson and Sanofi Get BURNED.
Life Technologies Corporation (NASDAQ:LIFE) reports that it has commenced the shipping of its Ion Proton System, which is a smaller genome sequencing device that is less expensive and more accessible than what has been available. Thus far, genome-scale sequencing has only been possible at large centers or in core laboratories, since it required specialized molecular biology skills and an extensive information tech infrastructure.
On Thursday Omnicare Inc. (NYSE:OCR) chose interim Chief Executive John Workman to permanently replace John Figueroa, who exited in June. Workman had been the chief financial officer for the firm, which provides nursing homes with drugs; he will be replaced by Robert Kraft. Additionally, Omnicare has doubled its dividend to 14 cents per share and increased its repurchase program by $350 million, moving the total approved up to $498 million.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>